Cystic Fibrosis Reprograms Airway Epithelial IL-33 Release and Licenses IL-33-Dependent Inflammation.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

16 citing papers in PubMed, 22 citations in OpenAlex.

1. Immune Modulation in Peripheral Blood of Cystic Fibrosis Patients Following Ex Vivo Co-Culture with Mesenchymal Stem Cells.Cells · 2026
   Article
2. Are Sputum High Mobility Group Box 1 and D-Dimer Changes Relevant Markers of Tissue Damage and Fibrinolysis in Cystic Fibrosis?Pathophysiology : the official journal of the International Society for Pathophysiology · 2026
   Article
3. The IL-33-ILC2 axis: a key regulator of type 2 immunity in respiratory disease.Frontiers in immunology · 2026
   Review
4. Mesenchymal stromal cell extracellular vesicles reduceAmerican journal of physiology. Lung cellular and molecular physiology · 2025
   Article
5. Unraveling the mechanisms of virus-induced asthma exacerbation: epithelial injury, immune dysregulation, and novel interventions.Chinese medical journal pulmonary and critical care medicine · 2025
   Review
6. Let-7b-5p loaded Mesenchymal Stromal Cell Extracellular Vesicles reducebioRxiv : the preprint server for biology · 2025
   Article
7. CFTR negatively reprograms Th2 cell responses, and CFTR potentiation restrains allergic airway inflammation.JCI insight · 2025
   Article
8. The Cystic Fibrosis Transmembrane Conductance Receptor Brakes Allergic Airway Inflammation.Immunological reviews · 2025
   Review
9. Type 2 inflammation in cystic fibrosis is a predictor of mortality and targeted with CFTR modulator therapy.Allergy · 2024
   Article
10. Ciliary Function, Antigen Stasis and Asthma.International journal of molecular sciences · 2024
    Review
11. Advances in non-type 2 severe asthma: from molecular insights to novel treatment strategies.The European respiratory journal · 2024
    Review
12. Antigen stasis and airway nitrosative stress in human primary ciliary dyskinesia.American journal of physiology. Lung cellular and molecular physiology · 2024
    Article
13. The production, function, and clinical applications of IL-33 in type 2 inflammation-related respiratory diseases.Frontiers in immunology · 2024
    Review
14. ATP functions as a primary alarmin in allergen-induced type 2 immunity.American journal of physiology. Cell physiology · 2023
    Review
15. An ALARMINg Type 2 Response in Cystic Fibrosis-The Key to Understanding ABPA?American journal of respiratory and critical care medicine · 2023
    Article
16. Modulator-refractory cystic fibrosis: Defining the scope and challenges of an emerging at-risk population.Therapeutic advances in respiratory disease
    Review

Corrections and comments

• Commented on by
  An ALARMINg Type 2 Response in Cystic Fibrosis-The Key to Understanding ABPA?2023

Authors and funding

13 authors at 3 institutions in 1 country.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as